siRNA therapy decreases triglycerides in individuals with rare disorder

.ANALYSIS HIGHLIGHT.19 September 2024.

Plozasiran decreased triglyceride levels by 80% and reduced the risk of pancreatitis in people with consistent chylomicronemia, with or even without a hereditary prognosis.